82 completed. 82 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 82 | Completed 82 |
| Phase 2 | 8 | Completed 8 |
Follow Headache Disorders, Primary: new trials by email Literature Review of Headache Disorders, Primary trials Research Report on Headache Disorders, Primary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Compare the Blood Levels of Two Dosage Formulations of the Study Medicine in Healthy Adults ODT2 Test formulation, ODT Reference formulation - Migraine | Phase 1 | Completed | Pfizer | 36 | 2026-05-11 | 2026-09-04 |
| A Study to Learn About PRT-064040 Nasal Spray in Healthy Adult Subjects PRT-064040 nasal spray, Placebo - Migraine | Phase 1 | Completed | Sichuan Purity Pharmaceutical Technology Co., Ltd. | 80 | 2025-06-07 | 2025-12-04 |
| A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine Ubrogepant, Lu AG09222, Placebo - Migraine | Phase 1 | Completed | H. Lundbeck A/S | 43 | 2024-09-13 | 2025-10-14 |
| Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment Phase 1 Lidocaine hydrochloride, Methylprednisolone sodium succinate - Refractory Migraine | Phase 1 | Completed | The Cooper Health System | 10 | 2024-03-15 | 2025-11-04 |
| Bioequivalence Study to Compare Ibuprofen/ Paracetamol Tablets (200mg Ibuprofen/ 500mg Paracetamol) Versus Nuromol® Tablets (200mg Ibuprofen/ 500mg Paracetamol) Ibuprofen/ Paracetamol tablets, Nuromol® tablets - Migraine, Headache | Phase 1 | Completed | Humanis Saglık Anonim Sirketi | 36 | 2023-08-29 | 2023-12-22 |
| A Study to Compare Zavegepant Concentration Using Samples Collected From the Vein Versus Patient-Centric Microsampling Zavegepant 10 mg IN - Healthy | Phase 1 | Completed | Pfizer | 14 | 2023-07-10 | 2026-01-29 |
| A Clinical Trial Evaluated the Safety and Tolerability, Pharmacokinetic and Pharmacodynamics Profile, and Immunogenicity of a Single Dose of JS010 Injection in Healthy Subjects JS010 injection, Placebo - Migraine | Phase 1 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 48 | 2023-05-10 | 2026-07-17 |
| Sphenopalatine Ganglion Block Study Bupivacaine, angiocatheter - Sphenopalatine Ganglion Nerve Block | Phase 1 | Completed | Montefiore Medical Center | 220 | 2023-03-06 | 2024-10-08 |
| A Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-313 in Healthy Participants UB-313, Placebo - Migraine | Phase 1 | Completed | Axxium Life, Inc. | 40 | 2022-07-06 | 2026-11-04 |
| A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants Lu AG09222, Placebo - Migraine | Phase 1 | Completed | H. Lundbeck A/S | 52 | 2022-03-18 | 2022-11-10 |
| Repeat Dosing of Psilocybin in Migraine Headache Psilocybin, Placebo - Migraine Headache | Phase 1 | Completed | Yale University | 18 | 2021-08-10 | 2024-02-09 |
| Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers Treatment A: M207 3.8 mg "MiniMac", Treatment B: M207 3.8 mg "MACAP", Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0 - Migraine | Phase 1 | Completed | Zosano Pharma Corporation | 48 | 2021-06-24 | 2021-09-17 |
| Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine Atogepant, Ubrogepant - Migraine | Phase 1 | Completed | AbbVie | 26 | 2021-03-17 | 2022-06-16 |
| A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects Dihydroergotamine - Migraine, Migraine With Aura | Phase 1 | Completed | Satsuma Pharmaceuticals, Inc. | 36 | 2021-03-05 | 2022-04-20 |
| A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab Eptinezumab - Migraine in Children, Migraine | Phase 1 | Completed | H. Lundbeck A/S | 28 | 2020-08-04 | 2023-10-06 |
| The Evaluation of Pharmacokinetic/Pharmacodynamic Characteristics and Safety of QDX in Healthy Korean Male Subjects Topiramate - Migraine | Phase 1 | Completed | SK Chemicals Co., Ltd. | 42 | 2020-07-01 | 2020-10-27 |
| Effect of Ketamine Intranasal Spray in Treatment of Chronic Cluster Headache Ketamine - Cluster Headache | Phase 1 / Phase 2 | Completed | CCH Pharmaceuticals | 23 | 2019-11-20 | 2021-02-24 |
| Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Ubrogepant, Erenumab, Galcanezumab - Migraine | Phase 1 | Completed | Allergan | 40 | 2019-09-26 | 2021-03-10 |
| Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman ALD1910, Sumatriptan - Migraine | Phase 1 | Completed | H. Lundbeck A/S | 96 | 2019-09-24 | 2020-09-23 |
| A Study of Lasmiditan (LY573144) in Children Aged 6 to 17 With Migraine Lasmiditan - Migraine | Phase 1 | Completed | Eli Lilly and Company | 18 | 2019-07-22 | 2020-09-01 |
Showing 20 of 82. Sign in to see all of them.
Migraine Disorders (77) · Headache (8) · Cluster Headache (5) · Migraine with Aura (3) · Migraine without Aura (3) · Pain (3) · Back Pain (2) · Epilepsy (2) · Headache Disorders (2) · Hypertension (2) · Anxiety Disorders (1) · Asthma (1) · Chest Pain (1) · Diabetes Mellitus (1) · Emergencies (1)
Brain Diseases (82) · Central Nervous System Diseases (82) · Nervous System Diseases (82) · Headache Disorders (80) · Pathological Conditions, Signs and Symptoms (13) · Neurologic Manifestations (12) · Signs and Symptoms (12) · Pain (8) · Trigeminal Autonomic Cephalalgias (5) · Cardiovascular Diseases (2) · Neuromuscular Diseases (2) · Pathologic Processes (2) · Vascular Diseases (2) · Bronchial Diseases (1)
Sumatriptan (8) · lasmiditan (6) · erenumab (5) · Topiramate (4) · zolmitriptan (4) · Botulinum Toxins, Type A (3) · Dihydroergotamine (3) · Psilocybin (3) · eptinezumab (3) · galcanezumab (3) · ubrogepant (3) · Saline Solution (2) · telcagepant (2) · 2-(8-(3,5-difluorophenyl)-10-oxo-6,9-diazaspiro(4.5)dec-9-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro(indene-2,3'-pyrrolo(2,3-b)pyridin)-5-yl)acetamide (1) · 5-methyl-8-(4-methyl-piperazin-1-yl)-4-oxo-4H-chromene-2-carboxylic acid (4-morpholin-4-yl-phenyl)amide (1)
Eli Lilly and Company (8) · Amgen (6) · Merck Sharp & Dohme LLC (6) · H. Lundbeck A/S (4) · Pfizer (4) · GlaxoSmithKline (3) · Norwegian University of Science and Technology (3) · Yale University (3) · Zosano Pharma Corporation (3) · Acorda Therapeutics (2) · Alder Biopharmaceuticals, Inc. (2) · NuPathe Inc. (2) · Satsuma Pharmaceuticals, Inc. (2) · AbbVie (1) · Achelios Therapeutics (1)
United States (46) · Belgium (7) · Canada (5) · Australia (4) · Norway (3) · China (2) · Denmark (2) · Brazil (1) · Germany (1) · Japan (1) · Jordan (1) · Mexico (1) · Netherlands (1) · Puerto Rico (1) · South Korea (1)
Don Kellerman, PharmD (2) · Adriana Conforto, MD,PHD (1) · Andrew Eisen, MD (1) · Benjamin Friedman, MD (1) · Benoit Bailey, MD (1) · Brendan Smyth (1) · Charles Oh, MD (1)
PMID 19461827, PMID 20637969, PMID 22289113, PMID 22305246, PMID 23798725, PMID 23975906, PMID 23992438, PMID 25168404, PMID 25297013, PMID 26232105, PMID 27154997, PMID 30659611, PMID 30963506, PMID 31482569, PMID 31852816, PMID 31985049, PMID 32583902, PMID 33184743, PMID 33565026, PMID 33781209, PMID 34823467, PMID 35594123, PMID 38413540, PMID 38581739, PMID 40444655, PMID 40530489, PMID 41459830, PMID 41608705, PMID 42012062
2014 (1), 2016 (1), 2019 (1)